Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 19 | 2024 | 338 | 2.890 |
Why?
|
| Hydroxyurea | 2 | 2020 | 82 | 0.740 |
Why?
|
| Recombinases | 2 | 2024 | 22 | 0.410 |
Why?
|
| Glioma | 4 | 2007 | 491 | 0.400 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 78 | 0.370 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 8 | 0.370 |
Why?
|
| Antisickling Agents | 1 | 2011 | 18 | 0.360 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 136 | 0.360 |
Why?
|
| Acetamides | 1 | 2011 | 47 | 0.350 |
Why?
|
| Hemolysis | 1 | 2011 | 112 | 0.350 |
Why?
|
| Cytapheresis | 1 | 2009 | 1 | 0.340 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 204 | 0.310 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 129 | 0.300 |
Why?
|
| Anemia | 2 | 2022 | 339 | 0.290 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 8 | 0.280 |
Why?
|
| Capacity Building | 2 | 2025 | 23 | 0.280 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 39 | 0.270 |
Why?
|
| Child | 25 | 2025 | 24410 | 0.270 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2024 | 65 | 0.270 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 45 | 0.250 |
Why?
|
| Child, Preschool | 17 | 2024 | 14019 | 0.250 |
Why?
|
| Pain | 4 | 2017 | 462 | 0.240 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 20 | 0.240 |
Why?
|
| Neonatal Screening | 2 | 2017 | 184 | 0.230 |
Why?
|
| Blood Transfusion | 3 | 2021 | 310 | 0.220 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 49 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 1116 | 0.210 |
Why?
|
| Menorrhagia | 1 | 2024 | 75 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 3572 | 0.210 |
Why?
|
| Adolescent | 18 | 2024 | 19343 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 134 | 0.210 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 131 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.200 |
Why?
|
| Alleles | 2 | 2024 | 1614 | 0.200 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1088 | 0.200 |
Why?
|
| Angola | 2 | 2018 | 5 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 166 | 0.180 |
Why?
|
| Pediatrics | 3 | 2025 | 1165 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 415 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 235 | 0.180 |
Why?
|
| Humans | 35 | 2025 | 124906 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 225 | 0.170 |
Why?
|
| HIV Infections | 2 | 2022 | 1894 | 0.170 |
Why?
|
| Malaria | 1 | 2021 | 86 | 0.170 |
Why?
|
| Iron | 1 | 2022 | 266 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 162 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 60 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 205 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2010 | 126 | 0.160 |
Why?
|
| Hematology | 1 | 2018 | 38 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2022 | 309 | 0.150 |
Why?
|
| Female | 19 | 2024 | 66678 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2014 | 1364 | 0.140 |
Why?
|
| Male | 18 | 2024 | 61395 | 0.140 |
Why?
|
| Paper | 1 | 2017 | 7 | 0.140 |
Why?
|
| Algorithms | 1 | 2024 | 1624 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2010 | 299 | 0.140 |
Why?
|
| Quality Improvement | 3 | 2024 | 641 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 136 | 0.130 |
Why?
|
| Infant | 9 | 2024 | 12477 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 28 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 284 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 307 | 0.120 |
Why?
|
| Patient Care | 2 | 2018 | 99 | 0.120 |
Why?
|
| Magnesium | 1 | 2015 | 121 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 987 | 0.120 |
Why?
|
| Prognosis | 4 | 2024 | 4631 | 0.120 |
Why?
|
| Quality of Life | 3 | 2017 | 1944 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1311 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16345 | 0.110 |
Why?
|
| Body Height | 1 | 2014 | 215 | 0.110 |
Why?
|
| Neoplasms | 2 | 2014 | 2792 | 0.100 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2902 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 561 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8199 | 0.100 |
Why?
|
| Young Adult | 6 | 2023 | 9051 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 115 | 0.100 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 28 | 0.090 |
Why?
|
| Risk Factors | 6 | 2024 | 10285 | 0.090 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 14 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 9 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 574 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 1645 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 724 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1269 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5165 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 111 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 991 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 727 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 276 | 0.080 |
Why?
|
| Chest Pain | 1 | 2009 | 126 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 556 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 781 | 0.080 |
Why?
|
| Brain | 1 | 2010 | 2994 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2014 | 521 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 226 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 1024 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1120 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 193 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 1216 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 462 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1178 | 0.070 |
Why?
|
| Adult | 6 | 2024 | 29576 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3289 | 0.060 |
Why?
|
| beta-Globins | 1 | 2024 | 6 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 538 | 0.060 |
Why?
|
| Hospitals, Special | 1 | 2014 | 14 | 0.060 |
Why?
|
| Narcotics | 1 | 2014 | 63 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 153 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 226 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 70 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 347 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 83 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 218 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 143 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 231 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 188 | 0.050 |
Why?
|
| Middle Aged | 5 | 2015 | 26879 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 288 | 0.050 |
Why?
|
| Arginine | 1 | 2023 | 332 | 0.050 |
Why?
|
| Informed Consent | 1 | 2014 | 334 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 812 | 0.040 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 21 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 525 | 0.040 |
Why?
|
| United States | 3 | 2023 | 10909 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 397 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 285 | 0.040 |
Why?
|
| Aged | 3 | 2011 | 19835 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 320 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 710 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 479 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1397 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 770 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 172 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 9 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 1290 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 24 | 0.030 |
Why?
|
| Saponins | 1 | 2017 | 22 | 0.030 |
Why?
|
| Sulfites | 1 | 2017 | 30 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 287 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12405 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2017 | 63 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 135 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 3586 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 1287 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 696 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2051 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1780 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 281 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 376 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 328 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 248 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 3069 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 42 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 173 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 66 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 783 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 97 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 199 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 98 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 237 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 518 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 762 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 2448 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 191 | 0.030 |
Why?
|
| Incidence | 1 | 2001 | 3140 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 526 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 509 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 217 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 83 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 2881 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 303 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 3449 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 80 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 98 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 114 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 123 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 301 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1439 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 899 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 798 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 259 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 202 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 398 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6155 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 512 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2060 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 22 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 25 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1031 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 143 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 99 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1252 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3436 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 125 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 5846 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 689 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1586 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1358 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1812 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 2557 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3153 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6320 | 0.010 |
Why?
|